Moderna and Merck announce an investigational individualized neoantigen therapy
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients
NGS enables researchers to quickly sequence entire genomes and transcriptomes of organisms.
The session took place in the presence of Union Ministers Hardeep Singh Puri and Gen V K Singh along with Anil Agarwal, Rajya Sabha Member of Parliament
Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
To enable company to be future-ready by tapping potential in CDMO space
New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes
EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Subscribe To Our Newsletter & Stay Updated